Abstract ID: 6002 Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.
讲者：孙艳
单位：北京大学肿瘤医院
专家评述
讲者：杨坤禹
单位：华中科技大学同济医学院附属协和医院
Abstract ID: 5000 TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603).
讲者：陈守臻
单位：山东大学齐鲁医院
Abstract ID: 5005 A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Abstract ID: 5006 Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Abstract ID: 4513 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
讲者：虞巍
单位：北京大学第一医院
Abstract ID: LBA4500 EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study
Abstract ID: 4516 Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
讲者：杨勇
Abstract ID: 507 Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.
讲者：郝春芳
单位：天津肿瘤医院
